AAPL344.82-2.29 (-0.66%) ▼|ABBV285.63-0.76 (-0.27%) ▼|ABT103.47+0.37 (+0.36%) ▲|ACN246.40+11.24 (+4.78%) ▲|ADBE248.32-0.04 (-0.02%) ▼|AMAT407.12+11.19 (+2.83%) ▲|AMD561.27+1.01 (+0.18%) ▲|AMGN452.29+4.34 (+0.97%) ▲|AMT179.01-4.83 (-2.62%) ▼|AMZN253.58+0.48 (+0.19%) ▲|AVGO345.00+2.67 (+0.78%) ▲|AXP316.40+3.49 (+1.11%) ▲|BA165.92-2.26 (-1.34%) ▼|BAC50.84+0.16 (+0.31%) ▲|BKNG148.55-1.59 (-1.06%) ▼|BLK1,146.88+10.83 (+0.95%) ▲|BMY61.01-0.55 (-0.89%) ▼|BNY148.20+0.62 (+0.42%) ▲|BRK-B543.01+0.02 (+0.00%) ▲|C123.50+0.81 (+0.66%) ▲|CAT709.64-3.67 (-0.51%) ▼|CL91.98-0.19 (-0.21%) ▼|CMCSA21.66-0.19 (-0.85%) ▼|COF204.31+0.87 (+0.43%) ▲|COP148.95+0.99 (+0.67%) ▲|COST982.90-9.23 (-0.93%) ▼|CRM243.26+2.37 (+0.98%) ▲|CSCO110.51-0.88 (-0.79%) ▼|CVS90.74-0.39 (-0.43%) ▼|CVX229.48+1.25 (+0.55%) ▲|DE642.59+3.01 (+0.47%) ▲|DHR237.13+5.13 (+2.21%) ▲|DIS109.20-1.03 (-0.93%) ▼|DUK124.62-0.19 (-0.15%) ▼|EMR167.91+1.64 (+0.99%) ▲|FDX302.00-5.10 (-1.66%) ▼|GD353.63-1.27 (-0.36%) ▼|GE297.86+0.20 (+0.07%) ▲|GEV864.11-30.97 (-3.46%) ▼|GILD160.07+0.99 (+0.62%) ▲|GM80.03-0.51 (-0.63%) ▼|GOOG320.98+4.15 (+1.31%) ▲|GOOGL324.62+4.04 (+1.26%) ▲|GS919.41+7.64 (+0.84%) ▲|HD320.83+2.33 (+0.73%) ▲|HON218.80-0.01 (0.00%) ▼|IBM252.04+1.79 (+0.72%) ▲|INTC93.26-0.48 (-0.51%) ▼|INTU333.00+4.55 (+1.39%) ▲|ISRG447.90+2.02 (+0.45%) ▲|JNJ269.83+1.10 (+0.41%) ▲|JPM337.26+1.47 (+0.44%) ▲|KO91.66+0.48 (+0.53%) ▲|LIN507.09-1.56 (-0.31%) ▼|LLY1,292.56+10.65 (+0.83%) ▲|LMT620.84-2.15 (-0.35%) ▼|LOW199.79+1.61 (+0.81%) ▲|LRCX247.76+6.91 (+2.87%) ▲|MA614.07+4.22 (+0.69%) ▲|MCD251.93+2.46 (+0.99%) ▲|MDLZ62.12-0.24 (-0.38%) ▼|MDT95.56+1.61 (+1.71%) ▲|META616.33-3.87 (-0.62%) ▼|MMM172.33+0.75 (+0.44%) ▲|MO73.31-0.18 (-0.24%) ▼|MRK141.58-0.25 (-0.17%) ▼|MS187.89+0.98 (+0.52%) ▲|MSFT529.84-1.49 (-0.28%) ▼|MU968.67+39.91 (+4.30%) ▲|NEE81.77-0.65 (-0.79%) ▼|NFLX61.87-0.65 (-1.04%) ▼|NKE37.53-0.04 (-0.09%) ▼|NOW153.52-1.26 (-0.81%) ▼|NVDA217.52-0.43 (-0.20%) ▼|ORCL130.78+0.25 (+0.19%) ▲|PEP132.45-1.05 (-0.79%) ▼|PFE29.73-0.08 (-0.25%) ▼|PG159.07-0.16 (-0.10%) ▼|PLTR195.32-3.42 (-1.72%) ▼|PM202.57-0.05 (-0.02%) ▼|QCOM183.07-1.10 (-0.60%) ▼|RTX195.30+0.70 (+0.36%) ▲|SBUX103.24+0.20 (+0.19%) ▲|SCHW88.58-0.72 (-0.81%) ▼|SO92.58-0.08 (-0.08%) ▼|SPG211.83-0.46 (-0.21%) ▼|T20.78-0.16 (-0.76%) ▼|TMO710.53+17.51 (+2.53%) ▲|TMUS145.19-1.64 (-1.12%) ▼|TSLA399.09-8.37 (-2.05%) ▼|TXN308.84-0.08 (-0.02%) ▼|UBER64.94-0.84 (-1.28%) ▼|UNH414.28+3.89 (+0.95%) ▲|UNP299.13-0.75 (-0.25%) ▼|UPS104.92-1.17 (-1.10%) ▼|USB59.61-0.13 (-0.22%) ▼|V401.52-0.34 (-0.08%) ▼|VZ43.52-0.42 (-0.94%) ▼|WFC83.44+0.78 (+0.94%) ▲|WMT118.83-0.49 (-0.41%) ▼|XOM181.67+1.76 (+0.98%) ▲|AAPL344.82-2.29 (-0.66%) ▼|ABBV285.63-0.76 (-0.27%) ▼|ABT103.47+0.37 (+0.36%) ▲|ACN246.40+11.24 (+4.78%) ▲|ADBE248.32-0.04 (-0.02%) ▼|AMAT407.12+11.19 (+2.83%) ▲|AMD561.27+1.01 (+0.18%) ▲|AMGN452.29+4.34 (+0.97%) ▲|AMT179.01-4.83 (-2.62%) ▼|AMZN253.58+0.48 (+0.19%) ▲|AVGO345.00+2.67 (+0.78%) ▲|AXP316.40+3.49 (+1.11%) ▲|BA165.92-2.26 (-1.34%) ▼|BAC50.84+0.16 (+0.31%) ▲|BKNG148.55-1.59 (-1.06%) ▼|BLK1,146.88+10.83 (+0.95%) ▲|BMY61.01-0.55 (-0.89%) ▼|BNY148.20+0.62 (+0.42%) ▲|BRK-B543.01+0.02 (+0.00%) ▲|C123.50+0.81 (+0.66%) ▲|CAT709.64-3.67 (-0.51%) ▼|CL91.98-0.19 (-0.21%) ▼|CMCSA21.66-0.19 (-0.85%) ▼|COF204.31+0.87 (+0.43%) ▲|COP148.95+0.99 (+0.67%) ▲|COST982.90-9.23 (-0.93%) ▼|CRM243.26+2.37 (+0.98%) ▲|CSCO110.51-0.88 (-0.79%) ▼|CVS90.74-0.39 (-0.43%) ▼|CVX229.48+1.25 (+0.55%) ▲|DE642.59+3.01 (+0.47%) ▲|DHR237.13+5.13 (+2.21%) ▲|DIS109.20-1.03 (-0.93%) ▼|DUK124.62-0.19 (-0.15%) ▼|EMR167.91+1.64 (+0.99%) ▲|FDX302.00-5.10 (-1.66%) ▼|GD353.63-1.27 (-0.36%) ▼|GE297.86+0.20 (+0.07%) ▲|GEV864.11-30.97 (-3.46%) ▼|GILD160.07+0.99 (+0.62%) ▲|GM80.03-0.51 (-0.63%) ▼|GOOG320.98+4.15 (+1.31%) ▲|GOOGL324.62+4.04 (+1.26%) ▲|GS919.41+7.64 (+0.84%) ▲|HD320.83+2.33 (+0.73%) ▲|HON218.80-0.01 (0.00%) ▼|IBM252.04+1.79 (+0.72%) ▲|INTC93.26-0.48 (-0.51%) ▼|INTU333.00+4.55 (+1.39%) ▲|ISRG447.90+2.02 (+0.45%) ▲|JNJ269.83+1.10 (+0.41%) ▲|JPM337.26+1.47 (+0.44%) ▲|KO91.66+0.48 (+0.53%) ▲|LIN507.09-1.56 (-0.31%) ▼|LLY1,292.56+10.65 (+0.83%) ▲|LMT620.84-2.15 (-0.35%) ▼|LOW199.79+1.61 (+0.81%) ▲|LRCX247.76+6.91 (+2.87%) ▲|MA614.07+4.22 (+0.69%) ▲|MCD251.93+2.46 (+0.99%) ▲|MDLZ62.12-0.24 (-0.38%) ▼|MDT95.56+1.61 (+1.71%) ▲|META616.33-3.87 (-0.62%) ▼|MMM172.33+0.75 (+0.44%) ▲|MO73.31-0.18 (-0.24%) ▼|MRK141.58-0.25 (-0.17%) ▼|MS187.89+0.98 (+0.52%) ▲|MSFT529.84-1.49 (-0.28%) ▼|MU968.67+39.91 (+4.30%) ▲|NEE81.77-0.65 (-0.79%) ▼|NFLX61.87-0.65 (-1.04%) ▼|NKE37.53-0.04 (-0.09%) ▼|NOW153.52-1.26 (-0.81%) ▼|NVDA217.52-0.43 (-0.20%) ▼|ORCL130.78+0.25 (+0.19%) ▲|PEP132.45-1.05 (-0.79%) ▼|PFE29.73-0.08 (-0.25%) ▼|PG159.07-0.16 (-0.10%) ▼|PLTR195.32-3.42 (-1.72%) ▼|PM202.57-0.05 (-0.02%) ▼|QCOM183.07-1.10 (-0.60%) ▼|RTX195.30+0.70 (+0.36%) ▲|SBUX103.24+0.20 (+0.19%) ▲|SCHW88.58-0.72 (-0.81%) ▼|SO92.58-0.08 (-0.08%) ▼|SPG211.83-0.46 (-0.21%) ▼|T20.78-0.16 (-0.76%) ▼|TMO710.53+17.51 (+2.53%) ▲|TMUS145.19-1.64 (-1.12%) ▼|TSLA399.09-8.37 (-2.05%) ▼|TXN308.84-0.08 (-0.02%) ▼|UBER64.94-0.84 (-1.28%) ▼|UNH414.28+3.89 (+0.95%) ▲|UNP299.13-0.75 (-0.25%) ▼|UPS104.92-1.17 (-1.10%) ▼|USB59.61-0.13 (-0.22%) ▼|V401.52-0.34 (-0.08%) ▼|VZ43.52-0.42 (-0.94%) ▼|WFC83.44+0.78 (+0.94%) ▲|WMT118.83-0.49 (-0.41%) ▼|XOM181.67+1.76 (+0.98%) ▲|
10 C
New York
Wednesday, October 28, 2026

Tag: TRI

newsFORsourcecompanycontentinformation1releasesmarket

On Lok Documentary Series Wins Two Telly Awards

"Combating Seniors' Loneliness" Earns Silver and Bronze in Nonprofit and Public Service Categories SAN FRANCISCO, June 11, 2025 /PRNewswire/ -- On Lok is proud...

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

First patient in Cohort B achieved CR after 2nd dose of TCB008EDINBURGH, Scotland, June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a...

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER

The clinical trial at Linkoping University will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, June 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF)...

Kanazawa University research: High-speed AFM and 3D modelling help towards understanding the dynamics of a protein implicated in several cancers

KANAZAWA, Japan, June 11, 2025 /PRNewswire/ -- Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University observe and model how the enzyme ADAR1 interacts...

Results from Phase 1/2 Study of Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to...

CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from the Phase 1/2 study (KL264-01/MK-2870-001)...

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of...

Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT

SHANGHAI, June 10, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that the China National Medical Products Administration (NMPA) has accepted the...

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium...

Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema...

EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6RImprovements in Visual Acuity and Retinal Edema Observed at All Dose LevelsNo Safety Issues Observed Following a...

VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation – Agreeing the Phase 2 Trial to Be...

HONG KONG and WENZHOU, China, June 9, 2025 /PRNewswire/ -- VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs,...

Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the...

EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including...

Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases

STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase...

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World’s First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy

HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions...

YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia...

SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTRI

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers